New HIV pill VH4770359 enters first human safety tests
NCT ID NCT07525544
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new experimental HIV drug called VH4770359 in 214 healthy adults aged 18-55. The goal is to check its safety, side effects, and how the body processes it. Participants will take either the drug or a placebo, and some will also receive midazolam to see if the new drug interacts with other medicines. Results will help design future studies in people living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VH4770359 (an experimental oral antiretroviral drug)
What this could lead to
If successful, this could lead to a new oral medication for controlling HIV, offering another option for people living with the virus.
What could go wrong
This is a very early, first-in-human study in healthy people, not those with HIV. It only tests safety and dosing; it may not work in patients or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••